Back to top
Share

Cannabis Science Extracts Kill Cancer Cells In Cancer Patients Being Treated Through Its Licensed Distributor Rockbrook

Daily Dose 2011-02-23 0 comments

Dr. Robert Melamede, speaking in Denver, Colorado last year during a medical cannabis seminar that also featured Irvine Rosenfeld, the second federal medical marijuana patient to enter the government program due to tumors throughout his entire body. (Photo credit: MedicalMarijuana411.com)

Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announceĀ that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells.

In conjunction with Rockbrook, its Colorado-licensed dispensary, Cannabis Science consulted with a variety of cancer patients who were seeking to inform themselves of the current peer reviewed scientific literature, regarding the historical use of cannabis to treat “tumorsā€.

“We are on the verge of a revolution in medicine… State generated results give us a unique ability to acquire scientific and clinical data for cannabis-based cancer treatments. Ā As previously announced, we will use our new laboratory facility to house analytical instrumentation, tissue culture, clean rooms and additional necessary equipment… to allow for the necessary FDA clinical trials.ā€ ~ Dr. Robert J. Melamede, the CEO and President of Cannabis Science Inc.

Unlike most conventional cancer treatments, cannabis has an outstanding safety profile, and patients in states with medical marijuana laws are able to make an informed decision to legally try various cannabis preparations to determine what is most effective for their particular condition.

Some of these scientifically informed patients have chosen to self-administer Cannabis Science extracts supplied by Rockbrook to treat their own cancers.

Cannabis Science is delighted that patients areĀ reporting dramatic improvements in their conditions, including basal cell carcinoma, non-small cell lung cancer accompanied by COPD (chronic obstructive pulmonary disease), ovarian cancer, and glioma.

For example, a patient with basal cell carcinoma used a topical formulation to dramatically and rapidly eliminate her obvious skin cancer. Meanwhile, patients with internal tumors used oral formulations for their treatment. We currently await more complete clinical evaluations of the patientsā€™ own reports of dramatic health improvements coincident with tumor shrinkage and disappearance.

Dr. Robert J. Melamede, the CEO and President of Cannabis Science Inc., stated, “We will pursue and acquire intra-state generated data to make these cancer medicines available to the public at large as rapidly as possible. To accomplish this goal, we will seek accelerated FDA approval. We are on the verge of a revolution in medicine. Cannabis is now returning to modern medicine for all the right reasons. State generated results give us a unique ability to acquire scientific and clinical data for cannabis-based cancer treatments. As previously announced, we will use our new laboratory facility to house analytical instrumentation, tissue culture, clean rooms and additional necessary equipment. This facility will meet or exceed all federal, state, and local requirements to allow for the necessary for FDA clinical trials.ā€

Cannabis Science expects to hold a press conference soon to formally announce its cancer formulation progress and future plans forĀ cancer treatments. Brand names for our new cancer treatment drugs are currently being vetted through the company attorney for future commercial use.